NasdaqGS:DVAXBiotechs
Assessing Dynavax After Recent Vaccine Progress and a 140% Five Year Share Price Surge
If you are wondering whether Dynavax Technologies is quietly turning into a value opportunity or just another biotech rollercoaster, you are in the right place.
The stock has slipped about 4% over the last week but is still up roughly 9.2% over the past month, even though it remains down around 15.0% year to date and 14.5% over the last year, after a strong 140.0% gain over five years.
Recent attention has centered on Dynavax's expanding role in vaccine adjuvants and partnerships that aim to...